Exploring a new approach to overcome drug resistance in triple negative breast cancer
Targeting cell fusion as a novel strategy to tackle JQ1 resistance in triple negative breast cancer
This study is looking at how combining triple negative breast cancer cells with immune cells might help make a treatment called JQ1 work better for patients, and it aims to find new ways to improve care based on individual cancer traits.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Benedict College NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-11081022 on NIH RePORTER |
What this research studies
This research investigates how targeting cell fusion between triple negative breast cancer (TNBC) cells and immune cells can help overcome resistance to a specific cancer treatment called JQ1. The study aims to understand the mechanisms behind this resistance, particularly focusing on a protein that facilitates cell fusion. By examining how these fused cells behave, the researchers hope to develop strategies that can enhance the effectiveness of JQ1 in treating TNBC. Patients may be involved in this research to help identify the best therapeutic approaches based on their unique cancer characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who may be facing challenges with current treatment options.
Not a fit: Patients with non-triple negative breast cancer or those who are not currently undergoing treatment for breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with triple negative breast cancer, improving their chances of response to therapy.
How similar studies have performed: While the approach of targeting cell fusion in cancer treatment is relatively novel, preliminary studies have shown promising results in understanding drug resistance mechanisms.
Where this research is happening
Columbia, United States
- Benedict College — Columbia, United States (Active)
Researchers
- Principal investigator: Ai, Walden — Benedict College
- Study coordinator: Ai, Walden
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.